Article title: Singapore's $10.2 Billion Revenue Stops Being Reported, SEC Sets Its Sights on 英伟达's Books
Body:
Singapore's $10.2 Billion Revenue Stops Being Reported, SEC Sets Its Sights on 英伟达's Books
In the quarter ended July 2025, 英伟达's billings in Singapore reached $10.2 billion, accounting for 22% of total revenue; after that, the company stopped disclosing this item separately, saying customers were merely invoiced in Singapore while the chips were almost all shipped elsewhere. What the SEC's civil investigation wants to ask is: did this disclosure approach mislead investors?

- SEC opens a civil investigation into 英伟达, examining whether disclosures misled investors
- Singapore billings of $10.2 billion, 22% of total revenue, no longer reported after July 2025
- 英伟达 says customers are invoiced in Singapore and chips are almost all shipped elsewhere
- US Treasury Secretary gives the board and outside counsel 10 days to explain whether there were illegal sales
Flip through 英伟达's latest few quarterly reports and you'll notice the "Singapore" line is gone. In the quarter ended July 2025, billings there were still $10.2 billion, 22% of total revenue; after that, the company stopped listing it separately. Now the US Securities and Exchange Commission (SEC) has opened a civil investigation into the matter, asking whether 英伟达's disclosures misled investors—what it's examining is not whether the chips were sold, but whose books this money should be on and whether that was made clear to investors.
What the SEC wants to ask is "was it made clear"
The US Securities and Exchange Commission has opened a civil investigation into 英伟达, asking not whether the chips were sold, but whether the financial reports led investors astray.
The news was first reported by The Wall Street Journal. The investigation is civil in nature, not a criminal charge, and does not concern whether the products themselves are compliant—let's draw these two boundaries first, so that all subsequent discussion has a foothold. The civil investigation has only one target at its core: whether 英伟达's disclosures misled investors. In other words, the question is not whether the business was done, but whether the books told the story clearly.
The investigation collided with an adjustment in reporting methodology during the same period. The company's cessation of separately listing Singapore revenue occurred right after the quarter ended July 2025. The Singapore billings figure for that quarter will be broken down in the next section.
There is another track running in parallel. US Treasury Secretary 斯科特·贝森特 gave 10 days for 英伟达's board and outside counsel to explain whether the company pushed "seemingly irregular sales" to inflate performance. That statement is very blunt and points to sales actions, while the SEC is focused on the disclosure language—the two tracks ask about different things, yet they land on the same company and the same reporting period.
For ordinary investors, the direct impact of this matter is not on the product side. 英伟达's chips are still selling, customers are still ordering; what has changed is the granularity you can see when you open the financial reports. When a regional billings figure accounting for more than a fifth of revenue disappears from the table, what regulators want to press on is precisely this: was this change fully explained, or was it quietly glossed over? As for whose books this money should ultimately be on and what investors lost after reporting stopped, we have to start from that $10.2 billion billings figure.
22% of revenue disappeared from the reports
In 英伟达's latest quarterly revenue, more than $1 out of every $5 was booked under Singapore. This figure later no longer appeared separately.
According to WSJ, in the quarter ended July 2025, 英伟达's billings in Singapore were $10.2 billion, accounting for 22% of total revenue that quarter. This is a revenue measure for a separately listed region in the financial reports (a revenue line item counted by customer billing location), not the final destination of the chips. The company's own account is that customers are invoiced in Singapore and the chips are almost always shipped elsewhere.
What scale is this ratio? Removing it from the regional breakdown means investors lose a coordinate for horizontal comparison: you can no longer see from the financial reports how the scale of this revenue changes, and can only infer it backward from the total.
The most counterintuitive part is here: Singapore itself is not the consumer of these $10.2 billion in chips. The separation of billing location, shipping location, and final use location is standard practice in entrepot trade and is not itself irregular. But when a billing location accounts for 22% of total revenue, it is no longer just an accounting item but an entry point for judging the authenticity of demand—where the money comes from and where the goods go determines which market this revenue should be counted against.
The timing of the reporting halt is also worth noting. The quarter ended July 2025 was the last time Singapore revenue was listed separately; after that, this line item disappeared from the financial reports. The SEC's civil investigation is asking precisely whether the disclosures misled investors, and the two matters overlap in time. For ordinary investors, the direct impact is: the growth story that could once be cross-verified through regional breakdowns now has only the company's total figures. There is currently no public data for third-party re-testing, and no one can independently confirm the compositional change in this 22%.
The remaining roughly 6 minutes are for members.
The free portion ends here. Behind the wall there is also:
Key points behind the wall: how did % of revenue just vanish, and what exactly is the SEC investigating?
Values written like {{NAME_ab12cd34}} are placeholders for real values. Use them exactly as written, in replies and in tool calls alike: they are filled in with the real values before anything runs. Don't ask to verify them, and don't replace them with examples.